Literature DB >> 34341497

BDNF controls GABAAR trafficking and related cognitive processes via autophagic regulation of p62.

Toshifumi Tomoda1,2, Akiko Sumitomo3,4, Rammohan Shukla3,5, Yuki Hirota-Tsuyada4, Hitoshi Miyachi6, Hyunjung Oh3, Leon French3,7, Etienne Sibille8,9,10.   

Abstract

Reduced brain-derived neurotrophic factor (BDNF) and gamma-aminobutyric acid (GABA) neurotransmission co-occur in brain conditions (depression, schizophrenia and age-related disorders) and are associated with symptomatology. Rodent studies show they are causally linked, suggesting the presence of biological pathways mediating this link. Here we first show that reduced BDNF and GABA also co-occur with attenuated autophagy in human depression. Using mice, we then show that reducing Bdnf levels (Bdnf+/-) leads to upregulated sequestosome-1/p62, a key autophagy-associated adaptor protein, whose levels are inversely correlated with autophagic activity. Reduced Bdnf levels also caused reduced surface presentation of α5 subunit-containing GABAA receptor (α5-GABAAR) in prefrontal cortex (PFC) pyramidal neurons. Reducing p62 gene dosage restored α5-GABAAR surface expression and rescued PFC-relevant behavioral deficits of Bdnf+/- mice, including cognitive inflexibility and reduced sensorimotor gating. Increasing p62 levels was sufficient to recreate the molecular and behavioral profiles of Bdnf+/- mice. Collectively, the data reveal a novel mechanism by which deficient BDNF leads to targeted reduced GABAergic signaling through autophagic dysregulation of p62, potentially underlying cognitive impairment across brain conditions.
© 2021. The Author(s), under exclusive licence to American College of Neuropsychopharmacology.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34341497      PMCID: PMC8674239          DOI: 10.1038/s41386-021-01116-0

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN: 0893-133X            Impact factor:   7.853


  49 in total

Review 1.  Brain-Derived Neurotrophic Factor Expression in Individuals With Schizophrenia and Healthy Aging: Testing the Accelerated Aging Hypothesis of Schizophrenia.

Authors:  Farhana Islam; Benoit H Mulsant; Aristotle N Voineskos; Tarek K Rajji
Journal:  Curr Psychiatry Rep       Date:  2017-07       Impact factor: 5.285

2.  Region-specific neurotrophin imbalances in Alzheimer disease: decreased levels of brain-derived neurotrophic factor and increased levels of nerve growth factor in hippocampus and cortical areas.

Authors:  C Hock; K Heese; C Hulette; C Rosenberg; U Otten
Journal:  Arch Neurol       Date:  2000-06

3.  Decreased BDNF levels in CSF of drug-naive first-episode psychotic subjects: correlation with plasma BDNF and psychopathology.

Authors:  Anilkumar Pillai; Anvita Kale; Sadhana Joshi; Nilesh Naphade; M S V K Raju; Henry Nasrallah; Sahebarao P Mahadik
Journal:  Int J Neuropsychopharmacol       Date:  2009-11-27       Impact factor: 5.176

4.  Reduced brain-derived neurotrophic factor in prefrontal cortex of patients with schizophrenia.

Authors:  C S Weickert; T M Hyde; B K Lipska; M M Herman; D R Weinberger; J E Kleinman
Journal:  Mol Psychiatry       Date:  2003-06       Impact factor: 15.992

5.  Reduced neuroplasticity in aged rats: a role for the neurotrophin brain-derived neurotrophic factor.

Authors:  Francesca Calabrese; Gianluigi Guidotti; Giorgio Racagni; Marco A Riva
Journal:  Neurobiol Aging       Date:  2013-07-17       Impact factor: 4.673

6.  Expression of hippocampal brain-derived neurotrophic factor and its receptors in Stanley consortium brains.

Authors:  J S Dunham; J F W Deakin; F Miyajima; A Payton; C T Toro
Journal:  J Psychiatr Res       Date:  2009-04-18       Impact factor: 4.791

7.  Brain-derived neurotrophic factor signaling and subgenual anterior cingulate cortex dysfunction in major depressive disorder.

Authors:  Adam Tripp; Hyunjung Oh; Jean-Philippe Guilloux; Keri Martinowich; David A Lewis; Etienne Sibille
Journal:  Am J Psychiatry       Date:  2012-11       Impact factor: 18.112

8.  Molecular abnormalities of the hippocampus in severe psychiatric illness: postmortem findings from the Stanley Neuropathology Consortium.

Authors:  Michael B Knable; Beata M Barci; Maree J Webster; James Meador-Woodruff; E Fuller Torrey
Journal:  Mol Psychiatry       Date:  2004-06       Impact factor: 15.992

Review 9.  Brain-derived neurotrophic factor in mood disorders and antidepressant treatments.

Authors:  Eero Castrén; Masami Kojima
Journal:  Neurobiol Dis       Date:  2016-07-15       Impact factor: 5.996

10.  Molecular evidence for BDNF- and GABA-related dysfunctions in the amygdala of female subjects with major depression.

Authors:  J-P Guilloux; G Douillard-Guilloux; R Kota; X Wang; A M Gardier; K Martinowich; G C Tseng; D A Lewis; E Sibille
Journal:  Mol Psychiatry       Date:  2011-09-13       Impact factor: 15.992

View more
  4 in total

Review 1.  Serum and plasma levels of brain-derived neurotrophic factor in individuals with eating disorders (EDs): a systematic review and meta-analysis.

Authors:  Parnian Shobeiri; Sara Bagherieh; Parsa Mirzayi; Amirali Kalantari; Omid Mirmosayyeb; Antônio L Teixeira; Nima Rezaei
Journal:  J Eat Disord       Date:  2022-07-18

2.  The cAMP Response Element- Binding Protein/Brain-Derived Neurotrophic Factor Pathway in Anterior Cingulate Cortex Regulates Neuropathic Pain and Anxiodepression Like Behaviors in Rats.

Authors:  Jing Wen; Yaowei Xu; Zhixiang Yu; Yifan Zhou; Wenting Wang; Jingjie Yang; Yiming Wang; Qian Bai; Zhisong Li
Journal:  Front Mol Neurosci       Date:  2022-03-24       Impact factor: 5.639

3.  Olfactory dysfunction in patients with multiple sclerosis; A systematic review and meta-analysis.

Authors:  Omid Mirmosayyeb; Narges Ebrahimi; Mahdi Barzegar; Alireza Afshari-Safavi; Sara Bagherieh; Vahid Shaygannejad
Journal:  PLoS One       Date:  2022-04-19       Impact factor: 3.240

Review 4.  The role of neuroimmune and inflammation in pediatric uremia-induced neuropathy.

Authors:  Linfeng Zhu; Guoqin Tong; Fan Yang; Yijun Zhao; Guangjie Chen
Journal:  Front Immunol       Date:  2022-09-15       Impact factor: 8.786

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.